In last trading session, Biora Therapeutics Inc. (NASDAQ:BIOR) saw 1.13 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $0.24 trading at $0.01 or 1.92% at ring of the bell on the day assigns it a market valuation of $39.32M. That closing price of BIOR’s stock is at a discount of -1870.83% from its 52-week high price of $4.73 and is indicating a premium of 8.33% from its 52-week low price of $0.22. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.76 million shares which gives us an average trading volume of 1.25 million if we extend that period to 3-months.
For Biora Therapeutics Inc. (BIOR), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 1.50. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.07 in the current quarter.
Biora Therapeutics Inc. (NASDAQ:BIOR) trade information
Upright in the green during last session for gaining 1.92%, in the last five days BIOR remained trading in the red while hitting it’s week-highest on Monday, 11/21/22 when the stock touched $0.24 price level, adding 13.11% to its value on the day. Biora Therapeutics Inc.’s shares saw a change of -88.56% in year-to-date performance and have moved -4.59% in past 5-day. Biora Therapeutics Inc. (NASDAQ:BIOR) showed a performance of -43.60% in past 30-days. Number of shares sold short was 14.21 million shares which calculate 12.4 days to cover the short interests.
Biora Therapeutics Inc. (BIOR) estimates and forecasts
Statistics highlight that Biora Therapeutics Inc. is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -69.76% of value to its shares in past 6 months, showing an annual growth rate of 89.17% while that of industry is 4.40. Apart from that, the company came raising its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to increase by 84.80% in the current quarter and calculating 87.50% increase in the next quarter. This year revenue growth is estimated to fall -99.00% from the last financial year’s standing.
2 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $50k for the same. And 2 analysts are in estimates of company making revenue of $40k in the next quarter that will end on Dec 2022.
Biora Therapeutics Inc. is more likely to be releasing its next quarterly report between November 08 and November 14 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Biora Therapeutics Inc. (NASDAQ:BIOR)’s Major holders
Insiders are in possession of 10.29% of company’s total shares while institution are holding 28.44 percent of that, with stock having share float percentage of 31.70%. Investors also watch the number of corporate investors in a company very closely, which is 28.44% institutions for Biora Therapeutics Inc. that are currently holding shares of the company. Athyrium Capital Management, LP is the top institutional holder at BIOR for having 29.86 million shares of worth $20.9 million. And as of Jun 29, 2022, it was holding 16.00% of the company’s outstanding shares.
The second largest institutional holder is Neuberger Berman Group, LLC, which was holding about 6.54 million shares on Jun 29, 2022. The number of shares represents firm’s hold over 3.50% of outstanding shares, having a total worth of $4.58 million.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Jun 29, 2022, the former fund manager was holding 3.88 million shares of worth $2.71 million or 2.08% of the total outstanding shares. The later fund manager was in possession of 1.66 million shares on Jun 29, 2022, making its stake of worth around $1.16 million in the company or a holder of 0.89% of company’s stock.